Dysbiosis, GERD
Conditions
Keywords
Infant GERD, H2RA medication
Brief summary
The changes in the organisms making up the gut microbiota in infants who are taking anti-acid reflux medications (histamine 2 receptor antagonists) as compared to infants who are not taking these medications is not well-studied or understood. Whether these medications change the gut microbiota and microbiome, and what that change may imply for children on these medications, is the focus of this study.
Detailed description
Gut microbiota dysbiosis is associated with diseases ranging from localized gastrointestinal disorders to neurologic, respiratory, metabolic, hepatic, and cardiovascular illnesses. The microbial colonization of the infant gut is known to play a key role in immunologic and metabolic pathways impacting on human health. Disruptions during the complex process of microbial colonization have been shown to increase disease susceptibility during life. A variety of factors are known to influence the gut microbiota, including mode of delivery of neonate, host genetic factors, hose immune response, diet, xenobiotics and other drugs, infections, and environmental microbial exposures. The diagnosis of gastroesophageal reflux disease in the infant population has increased during the past two decades. Acid suppression medications are used commonly in infants for gastroesophageal reflux disease and other acid-related conditions despite little evidence of their efficacy. Multiple studies have shown adverse effects in pediatric patients using either proton pump inhibitors or H2 receptor antagonists, the two classes of acid suppression medications that are most frequently used in children. Some of these adverse effects may result from alterations in the microbiome caused by these medications. Prior studies have demonstrated significant changes in microbial composition of both gastric and intestinal microbiota with proton pump inhibitor use (5), but to the investigators' knowledge, no prior studies have looked at the effect of H2 receptor antagonists on the microbiome in healthy, full term infants.
Interventions
None listed
Sponsors
Nemours Children's Clinic
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
2 Months to 12 Months
Healthy volunteers
Yes
Inclusion criteria
* Full term, at least 2 months of age * No exposure OR at least 14 days of exposure to H2-receptor antagonist medication * No exposure to probiotics or antibiotics
Exclusion criteria
* Current or recent (within the past 14 days) gastrointestinal infection (viral, bacterial, or fungal) * Gastrointestinal mucosal disease, or have clinically significant constipation * Any history of exposure to proton pump inhibitors * Unvaccinated infants * Infants with weight-for-length either below the 3rd percentile for age or above the 97th percentile for age * Infants with rapid weight gain, defined as change in weight-for-length z-score exceeding +0.67 from birth to 4 months of age or birth to 6 months of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Microbiome taxa | At time of sampling - once at enrollment | 16S Metagenomic taxonomy of gut microbiome |
Countries
United States
Outcome results
None listed